Areas of Focus
- Anti-tumor drug development and mechanism research
- DNA damage repair pathway and nuclear protein intervention research
- Development of new drugs targeting the ubiquitin-proteasome pathway
Work Experience
- 2019-10~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
- 2016-10~2019-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
- 2016-02~2016-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
- 2012-09~2016-01 - Weill Cornell Medicine - Postdoc
Academic Background & Achievements
- 2007-09--2012-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 2003-09--2007-07 Bachelor's: Shandong University
Publications
- Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy, Jinxue He, 2024
- YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors, Jinxue He, 2023
- Identification of 1,2,4Triazolo4,3-apyrazine PARP1 inhibitors with overcome acquired resistance activities, Jinxue He, 2023
- Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance, Jinxue He, 2023
- SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy, Jinxue He, 2022
- Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone, Jinxue He, 2022
- Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold, Jinxue He, 2021
- Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers, Jinxue He, 2021
- Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer, Jinxue He, 2021
- Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors, Jinxue He, 2020
- Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity, Jinxue He, 2019
- Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression, Jinxue He, 2018
- Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors, Jinxue He, 2017
- Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, Jinxue He, 2017
- Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, Jinxue He, 2017
- PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis, Jinxue He, 2016
- PTEN Regulates DNA Replication Progression and Stalled Fork Recovery, Jinxue He, 2015
